清肝消瘿方治疗Graves眼病肝火旺盛证的临床研究
|
摘要
目的:通过与醋酸泼尼松治疗方案的对比研究,客观评价中药清肝消瘿方治疗GO的疗效和安全性。
方法:根据简单随机、非盲、对照的临床观察原则,入选76例符合GO诊断,以及中医辨证符合肝火旺盛标准的病人,皆完成观察。76例病人随机分为两组,其中中西结合治疗组(以下简称治疗组)38例,基础药物加清肝消瘿方治疗;西药对照组(以下简称对照组)38例,基础药物加醋酸泼尼松治疗。疗程均为8周.
结果:①对症状体征的改善作用:治疗组各种症状体征改善程度均优于对照组,其中目胀流泪两组改善程度相比有显著统计学意义(P＜0.01)、手指震颤改善程度相比有统计学意义(P＜0.05),心悸烦躁的改善程度相比接近有统计学意义(P=0.09);②突眼度、视力改善作用:治疗组眼球突出度改善情况明显优于对照组,组间对比有统计学意义(P＜0.05),两组治疗后视力均有显著改善(P＜0.01或P＜0.05),但组间对比无统计学意义(P＞0.05);③甲状腺激素及甲状腺相关抗体改善作用:两组TT3、TT4、FT3、FT4,均有显著下降(P＜0.01或P＜0.05),且TT3、FT3、FT4下降幅度优于对照组,但组间对比无统计学意义(P＞0.05),两组治疗后TGAb、TMAb、TRAb均有显著下降(P＜0.01或P＜0.05),且治疗组TGAb、TMAb下降水平明显优于对照组(P＜0.05):④安全性:在本研究中,应用中药清肝消瘿方对照组和西药醋酸泼尼松对照组均有良好的安全性,两组比较差异无明显统计学意义。
结论:应用清肝消瘿方的治疗组在改善患者突眼度、眼部自觉症状及临床高代谢症状方面其效果明显优于对照组;治疗组可改善患者异常的甲状腺功能,其甲功(TT3、TT4、FT3、FT4)下降幅度、TSH上升幅度均优于对照组;治疗组具有调节异常甲状腺相关抗体(TRAb、TGAb、TMAb)的作用,具有免疫调节功能,对提高甲亢疗效,缩短病程,降低复发率有一定意义;清肝消瘦方安全,无毒副作用.
Objective:Treatment with prednisone acetate comparative study of the program,the objective evaluation of traditional Chinese medicine treatment QingGanXiaoYing prescription of the efficacy and safety.
Method:Based on simple random,non-blind,controlled clinical trial principles,in line with the 76 cases selected GO diagnosis,as well as the TCM Prosperity of hepatic fire standards in line with the patients,all completed observation.76 cases were randomly divided into two groups,which combines Chinese and Western treatment group(hereinafter referred to as the treatment group)38 cases,the basis of the drug plus side treatment QingGanXiaoYing prescription;Western medicine control group(hereinafter referred to as the control group) 38 cases,the basis of the drug plus acetate prednisone treatment.Courses are for 8 weeks.
Result:①The symptoms and signs of improvement:the treatment group improvements in a variety of symptoms and signs are better than the control group,which heads to improve the level of inflation in tears compared to the two groups with significant statistical significance (P＜0.01),finger tremor improved statistical significance compared(P＜0.05),irritability palpitations improvement was statistically significant compared to close to(P=0.09);②exophthalmos,the visual improvement:the treatment group after treatment to improve the situation exophthalmos obviously gifted in the control group,comparison between groups was statistically significant(P＜0.05),the two groups after treatment were significantly improved visual acuity(P＜0.01 or P＜0.05),but inter-group comparison was not significant(P＞0.05);③thyroid hormone and thyroid-associated antibodies to improve the role:the two groups after treatment TT3,TT4,FT3,FT4,were significantly decreased(P＜0.01 or P＜0.05),and TT3,FT3, FT4 decline was better than the control group,but Comparison between groups was not significant(P＞0.05),the two groups after treatment TGAb,TMAb,TRAb were significantly decreased(P＜0.01 or P＜0.05),after treatment,TGAb,TMAb decline significantly better than the control group(P＜0.05);④security:In this study,both of them have good security,no significant difference between the two groups statistically significant.
Conclusion:The treatment group in improving the degree of exophthalmos,eye symptoms and clinical symptoms of high metabolic its better than the control group alone;The treatment group may improve in patients with abnormal thyroid function,the thyroid function(TT3,TT4, FT3,FT4) decrease,TSH rise are better than the control group;The treatment group side with abnormal regulation of thyroid-associated antibodies(TRAb,TGAb,TMAb) the role of immune regulatory function,to improve the hyperthyroidism efficacy,shorten the course,reduce the relapse rate in a certain sense;QingGanXiaoYing Prescription security,non-toxic side effects.
方法:根据简单随机、非盲、对照的临床观察原则,入选76例符合GO诊断,以及中医辨证符合肝火旺盛标准的病人,皆完成观察。76例病人随机分为两组,其中中西结合治疗组(以下简称治疗组)38例,基础药物加清肝消瘿方治疗;西药对照组(以下简称对照组)38例,基础药物加醋酸泼尼松治疗。疗程均为8周.
结果:①对症状体征的改善作用:治疗组各种症状体征改善程度均优于对照组,其中目胀流泪两组改善程度相比有显著统计学意义(P＜0.01)、手指震颤改善程度相比有统计学意义(P＜0.05),心悸烦躁的改善程度相比接近有统计学意义(P=0.09);②突眼度、视力改善作用:治疗组眼球突出度改善情况明显优于对照组,组间对比有统计学意义(P＜0.05),两组治疗后视力均有显著改善(P＜0.01或P＜0.05),但组间对比无统计学意义(P＞0.05);③甲状腺激素及甲状腺相关抗体改善作用:两组TT3、TT4、FT3、FT4,均有显著下降(P＜0.01或P＜0.05),且TT3、FT3、FT4下降幅度优于对照组,但组间对比无统计学意义(P＞0.05),两组治疗后TGAb、TMAb、TRAb均有显著下降(P＜0.01或P＜0.05),且治疗组TGAb、TMAb下降水平明显优于对照组(P＜0.05):④安全性:在本研究中,应用中药清肝消瘿方对照组和西药醋酸泼尼松对照组均有良好的安全性,两组比较差异无明显统计学意义。
结论:应用清肝消瘿方的治疗组在改善患者突眼度、眼部自觉症状及临床高代谢症状方面其效果明显优于对照组;治疗组可改善患者异常的甲状腺功能,其甲功(TT3、TT4、FT3、FT4)下降幅度、TSH上升幅度均优于对照组;治疗组具有调节异常甲状腺相关抗体(TRAb、TGAb、TMAb)的作用,具有免疫调节功能,对提高甲亢疗效,缩短病程,降低复发率有一定意义;清肝消瘦方安全,无毒副作用.
Objective:Treatment with prednisone acetate comparative study of the program,the objective evaluation of traditional Chinese medicine treatment QingGanXiaoYing prescription of the efficacy and safety.
Method:Based on simple random,non-blind,controlled clinical trial principles,in line with the 76 cases selected GO diagnosis,as well as the TCM Prosperity of hepatic fire standards in line with the patients,all completed observation.76 cases were randomly divided into two groups,which combines Chinese and Western treatment group(hereinafter referred to as the treatment group)38 cases,the basis of the drug plus side treatment QingGanXiaoYing prescription;Western medicine control group(hereinafter referred to as the control group) 38 cases,the basis of the drug plus acetate prednisone treatment.Courses are for 8 weeks.
Result:①The symptoms and signs of improvement:the treatment group improvements in a variety of symptoms and signs are better than the control group,which heads to improve the level of inflation in tears compared to the two groups with significant statistical significance (P＜0.01),finger tremor improved statistical significance compared(P＜0.05),irritability palpitations improvement was statistically significant compared to close to(P=0.09);②exophthalmos,the visual improvement:the treatment group after treatment to improve the situation exophthalmos obviously gifted in the control group,comparison between groups was statistically significant(P＜0.05),the two groups after treatment were significantly improved visual acuity(P＜0.01 or P＜0.05),but inter-group comparison was not significant(P＞0.05);③thyroid hormone and thyroid-associated antibodies to improve the role:the two groups after treatment TT3,TT4,FT3,FT4,were significantly decreased(P＜0.01 or P＜0.05),and TT3,FT3, FT4 decline was better than the control group,but Comparison between groups was not significant(P＞0.05),the two groups after treatment TGAb,TMAb,TRAb were significantly decreased(P＜0.01 or P＜0.05),after treatment,TGAb,TMAb decline significantly better than the control group(P＜0.05);④security:In this study,both of them have good security,no significant difference between the two groups statistically significant.
Conclusion:The treatment group in improving the degree of exophthalmos,eye symptoms and clinical symptoms of high metabolic its better than the control group alone;The treatment group may improve in patients with abnormal thyroid function,the thyroid function(TT3,TT4, FT3,FT4) decrease,TSH rise are better than the control group;The treatment group side with abnormal regulation of thyroid-associated antibodies(TRAb,TGAb,TMAb) the role of immune regulatory function,to improve the hyperthyroidism efficacy,shorten the course,reduce the relapse rate in a certain sense;QingGanXiaoYing Prescription security,non-toxic side effects.
引文
[1]隋·巢元方.诸病源候论[M].北京:人民卫生出版社影印本,1982.
[2]黄帝内经灵枢[M].北京:人民卫生出版社,1959.
[3]宋·陈言.三因极一病证方论[M].北京:人民卫生出版社,1957.
[4]宋·赵估.圣济总录[M].北京:人民卫生出版社,1982.
[5]明·陈实功.外科正宗[M].北京:人民卫生出版社,1955.
[6]周华祥,王万杰.中医眼科对鹘眼凝睛的认识与治疗[J].2006,24(12):19-20.
[7]汉·张仲景.仲景全书·伤寒论.第4版,[M]北京:中医古籍出版社,1997.6.
[8]唐·孙思邀.千金要方[M].北京:人民卫生出版社,1955.
[9]唐·王熹.外台秘要[M].北京:人民卫生出版社,1955.
[10]宋·许书微.普济本事方[M].上海:上海科学出版社,1959.
[11]邱志济.朱良春治疗甲亢囊肿结节突眼的特色发挥[J].辽宁中医杂志,2004,31(10):809-810.
[12]邝秀英,廖世煌.辨治甲亢性甲状腺肿大的经验[J].辽宁中医杂志,2001,28(7):398.
[13]高允珊.益气养阴法治疗甲状腺功能亢进症临床观察[J].广西中医药,2005,28(3):23.
[14]孙国胜,张京峰.孙六合教授针药并用治疗甲亢的经验[J].中医药学刊,2005,23(11):1948-1949.
[15]吴正平,谭为.疏肝健脾汤治疗甲亢46例临床观察[J].四川中医,2006,24(11):65.
[16]林兰,李鸣摘,刘喜明,等.中药甲亢宁治疗阴虚阳亢型甲状腺功能亢进症的临床研究[J].中国中西医结合杂志,1999,19(3):144-146.
[17]方壮生,赵华妹,张卫民.血竭联合他巴唑治疗甲状腺机能亢进症39例[J].中国中西医结合杂志,2000,20(2):532.
[18]刘清平,廖世煌.辨治甲状腺机能亢进突眼症经验[J].浙江中医杂志,2001,(1):4-5.
[19]简小兵.李赛美治疗甲状腺功能亢进症经验[J].四川中医,2006,24(11):1.
[20]钟鲁梅,金艳.清亢合剂治疗甲状腺功能亢进临床研究[J].山东中医药大学学报,2006,30(4):306-307.
[21]文东,张艳君.中西医结合治疗Graves病32例分析[J].黑龙江中医药,2008,(1):1.
[22]李红,葛芳芳.徐蓉娟教授辨治毒性弥漫性甲状腺肿浸润性突眼经验介绍[J].新中医,2005,37(4):21-22.
[23]张勇.辨证治疗“甲亢”突眼30例[J].河南中医,2007,27(5):54-55.
[24]罗红娥.中西医结合治疗甲亢突眼31例[J].江西中医药,2005,12(32):45-46.
[25]唐红.从肝论治格雷夫斯眼病[J].上海中医药杂志,2007,41(6):60-61.
[26]刘春红.中西医结合治疗甲亢突眼36例总结[J].湖南中医杂志,2001,17(3):9-10.
[27]廖世煌.甲眼消合并他巴唑治疗甲状腺机能亢进症突眼的临床观察[J].中国中西医结合杂志,2000,20(6):433.
[28]张大平.益阴消突汤治疗甲状腺机能亢进症突眼45例[J].江西中医药,2006,(5):9-10.
[29]李红,徐蓉娟.“平目汤2号”治疗非活动期Graves病浸润性突眼临床观察[J].上海中医药杂志, 2008,42(8):50-52.
[30]朱垚、王旭.“二夏消瘿汤”干预Graves病的临床研究[J].江苏中医药,2008,40(6):25-26.
[31]崇礼.左旋咪唑和双黄连治疗眼型Graves病[J].中国实用眼科杂志,1995,13(6):382.
[32]张太阳,张启发.黄芪对Graves病患者T淋巴细胞亚群的影响[J].江西中医学院学报,1995,(2):22.
[33]王晓敏,王晓玲.雷公藤多甙治疗甲亢突眼的临床研究[J].江苏中医药,1995,16(10):41.
[34]唐灵,梁志清.雷公藤多甙对Graves病甲状腺功能及自身抗体的影响[J].中国中西医结合杂志,2003,23(4):294-295.
[35]沐榕,陈美爱.针刺为主治疗甲状腺机能亢进稳定期浸润性突眼症的临床观察[J].中国中西医结合杂志,2000,20(3):226-227.
[36]王晓燕.针刺治疗突眼性甲状腺肿临床疗效观察[J].中国针灸,2002,22(1):13.
[37]陈修贵,孙克兴.针刺治疗Graves眼病患者突眼的免疫学机制探讨[J].中国中医药信息杂志,2004,11(5):381-382.
[38]李桂玲、刘原芳.挑治法治疗Graves眼病28例临床观察[J].中国中医急症,2006,15(7):728-729.
[39]黄立.中西药结合治疗眼型Graves病[J].中国中医眼科杂志,2000,10(4):223.
[40]唐爱华.中西医结合治疗甲亢突眼的临床观察[J].四川中医,2006,24(7):54-55.
[41]费大东.中西医结合治疗甲亢突眼35例[J].山东中医杂志,2004,23(8):485-486.
[42]李昌祁,阴慧清,张春凯,等.大庆地区十万人群Graves病流行病学凋查[J].中华医学杂志,2000,76(6):443.
[43]罗敏.Graves眼病的发病机制及其治疗策略[J].国外医学内分泌学分册,2003,23(6):372-373
[44]王爱萍.细胞因子在Graves眼病发病中的作用机理[J].国外医学内分泌学分册,2003,23(6):401-402.
[45]Noh JY,Hamada N,Inoue Y,etal.Thyroid-stimulating antibody is related to Graves'ophthalmopathy,but thyropin-binging inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves'disease [J].Thyroidism,2000,9:809-813.
[46]吴晓徽,陆汉魁,高云朝.甲状腺球蛋白的测量及临床应用价值[J].标记免疫分析与临床,2008,15(5):325-326.
[47]胡蜀红.Graves眼病的发病机理[J].国外医学内分泌学分册,2002,22(2):98-99.
[48]陈雷,李玉妹,滕卫平,等.Graves眼病IgG和细胞因子INF-Y对体外培养人眶后成纤维细胞的刺激作用[J].中国医科大学学报,2007,28(1):38-40.
[49]何为民.黏附分子在Graves眼病眼外肌原位表达的研究[J].中华眼科杂志,2001,37(4):267-268.
[50]何为民.Graves眼病的组织病理学研究[J].华西医学,2002,17(3):422-423.
[51]孙玲玲.Graves病候选基因多态性研究进展[J].国际遗传学杂志,2006,29(1):62-64.
[52]张胜兰,张秀英.Graves眼病的发病机理及治疗[J].山东医药,2001,4(6):57-58.
[53]孙华,焦秦.甲状腺相关眼病381例临床分析[J].中华内科杂志,2006,45(5):400-402.
[54]邹新农.Graves病眼眶的CT研究[J].中国CT和MRI杂志,2006,4(1):11-13.
[55]陈德才,朱泓,陈红艳,等.甲基强的松龙与地塞米松加氨甲蝶呤冲击治疗Graves眼病的近期临床 疗效观察[J].中华内分泌代谢杂志,2002,18(4):321-322.
[56]王坚.Groves眼病部分免疫抑制剂疗效探讨[J].中华内科杂志,2004,43(2):125-126.
[57]Heufelder AE.[J].Endocrinol Invest,1997,20(Suppl)7:50.
[58]Colao A etal.Eur[J].Endocrinol,2000,143(Suppl):S35.
[59]Krassas GE etal.Eur[J].Endocrinol,2001,144(4):311.
[60]BasehieriL,AntonelliA.Nardi5eral[J].ThyTOid,1998,7(4):579-585.
[61]Glinoerand Msehroogen:Aeta,Endoerinologiea(Copenh)1999,(2):149.
[62]曲宝林,王迎选,徐寿平.Graves眼病放射治疗121例临床观察[J].生物医学工程与临床,2007,11(3):210-211.
[63]Burch HB,Wartofsky L.Graves'ophthalmopathy:current concepts regarding pathogenesis and management[J].Eendocr REV,1993;14:747.
[64]郑筱萸主编.中药新药临床研究指导原则[M].中国科技出版社:2002.5.
[65]中国甲状腺疾病诊治指南.中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组,2007,4,15.
[66]陈灏珠.实用内科学(第12版)[M].北京:人民卫生出版社2005.
[67]国家技术监督局.中华人民共和国国家标准·中医临床诊疗术语·证候部分[S].北京:中国标准出版社,1997:4-8.
[68]岳式君,单忠艳,旷劲松,等.大剂量激素冲击疗法治疗浸润性突眼[J].中国医科大学学报,1996,25(3):316-317.
[69]薛明,冯怡.夏枯草化学成分及药理作用的研究概况[J].江苏中医药,2005,26(5):55-56.
[70]陈勤,曾炎贵,曹明成,等.夏枯草口服液抗炎镇痛作用研究[J].基层中医药杂志,2002,16(2):6.
[71]韩澎,崔亚君,郭洪祝,等.密蒙花化学成分及其活性研究[J].中草药,2004,35(10)1086-1090.
[72]宋毅,王玉娥,冯玲玲,等.枸杞多糖免疫调节作用的实验研究[J].湖北预防医学杂志,2000,11(3):161.
[73]施仁潮.枸杞子[M].杭州:浙江科学技术出版社,2002.12-22.
[74]邱静帆.车前子的药学研究及其应用[J].浙江中西医结合杂志,2002,12(1):55.
[75]张海燕.连翘化学成分及药理活性的研究进展[J].中药材,2000,23(10)657-660.
[76]舒华,向丽华.黄连药理作用及临床应用[J].甘肃中医,2004,17(12):5-6.
[77]许廷生,梁秀兰.黄连的临床应用[J].河南中医,2003,23(3)61.
[78]张秀明.茯苓药理作用研究概况[J].中药材,2001,24(6)446-449.
[79]冯宝民,余正江.炒白芥子中化学成分的研究[J].中草药,2008,39(3):331-334.
[80]李小莉,张迎庆.白芥子提取物的抗炎镇痛作用研究[J].现代中药研究与实践,2007,21(6):28-30.
[81]阮金兰,赵钟祥.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9):965-969.
[82]周强,栗占国.白芍总苷的药理作用及其在自身免疫性疾病中的应用[J].中国新药与临床杂志,2003,22(11):687-690.
[83]惠寿年.国内对甘草化学成分的研究进展[J].中草药,1999,30(4):313-3151.
[84]王惠敏.甘草药理作用及其临床应用[J].天津中医学院学报,2004,23(4):184-185.
[85]黄伟光,冯凭.Graves眼病治疗的现状与展望[J].国外医学·内分泌学分册,2001,21(6):317-318.
[86]杜建玲,李昌臣.甲基强的松龙冲击治疗54例Graves眼病的疗效观察[J].中国实用内科杂志2002,22(9):548.
[87]青华,张素华.大剂量甲基强的松龙静脉冲击治疗浸润性突眼的疗效观察[J].内分泌外科杂志,2008,2(2):109-111.
[2]黄帝内经灵枢[M].北京:人民卫生出版社,1959.
[3]宋·陈言.三因极一病证方论[M].北京:人民卫生出版社,1957.
[4]宋·赵估.圣济总录[M].北京:人民卫生出版社,1982.
[5]明·陈实功.外科正宗[M].北京:人民卫生出版社,1955.
[6]周华祥,王万杰.中医眼科对鹘眼凝睛的认识与治疗[J].2006,24(12):19-20.
[7]汉·张仲景.仲景全书·伤寒论.第4版,[M]北京:中医古籍出版社,1997.6.
[8]唐·孙思邀.千金要方[M].北京:人民卫生出版社,1955.
[9]唐·王熹.外台秘要[M].北京:人民卫生出版社,1955.
[10]宋·许书微.普济本事方[M].上海:上海科学出版社,1959.
[11]邱志济.朱良春治疗甲亢囊肿结节突眼的特色发挥[J].辽宁中医杂志,2004,31(10):809-810.
[12]邝秀英,廖世煌.辨治甲亢性甲状腺肿大的经验[J].辽宁中医杂志,2001,28(7):398.
[13]高允珊.益气养阴法治疗甲状腺功能亢进症临床观察[J].广西中医药,2005,28(3):23.
[14]孙国胜,张京峰.孙六合教授针药并用治疗甲亢的经验[J].中医药学刊,2005,23(11):1948-1949.
[15]吴正平,谭为.疏肝健脾汤治疗甲亢46例临床观察[J].四川中医,2006,24(11):65.
[16]林兰,李鸣摘,刘喜明,等.中药甲亢宁治疗阴虚阳亢型甲状腺功能亢进症的临床研究[J].中国中西医结合杂志,1999,19(3):144-146.
[17]方壮生,赵华妹,张卫民.血竭联合他巴唑治疗甲状腺机能亢进症39例[J].中国中西医结合杂志,2000,20(2):532.
[18]刘清平,廖世煌.辨治甲状腺机能亢进突眼症经验[J].浙江中医杂志,2001,(1):4-5.
[19]简小兵.李赛美治疗甲状腺功能亢进症经验[J].四川中医,2006,24(11):1.
[20]钟鲁梅,金艳.清亢合剂治疗甲状腺功能亢进临床研究[J].山东中医药大学学报,2006,30(4):306-307.
[21]文东,张艳君.中西医结合治疗Graves病32例分析[J].黑龙江中医药,2008,(1):1.
[22]李红,葛芳芳.徐蓉娟教授辨治毒性弥漫性甲状腺肿浸润性突眼经验介绍[J].新中医,2005,37(4):21-22.
[23]张勇.辨证治疗“甲亢”突眼30例[J].河南中医,2007,27(5):54-55.
[24]罗红娥.中西医结合治疗甲亢突眼31例[J].江西中医药,2005,12(32):45-46.
[25]唐红.从肝论治格雷夫斯眼病[J].上海中医药杂志,2007,41(6):60-61.
[26]刘春红.中西医结合治疗甲亢突眼36例总结[J].湖南中医杂志,2001,17(3):9-10.
[27]廖世煌.甲眼消合并他巴唑治疗甲状腺机能亢进症突眼的临床观察[J].中国中西医结合杂志,2000,20(6):433.
[28]张大平.益阴消突汤治疗甲状腺机能亢进症突眼45例[J].江西中医药,2006,(5):9-10.
[29]李红,徐蓉娟.“平目汤2号”治疗非活动期Graves病浸润性突眼临床观察[J].上海中医药杂志, 2008,42(8):50-52.
[30]朱垚、王旭.“二夏消瘿汤”干预Graves病的临床研究[J].江苏中医药,2008,40(6):25-26.
[31]崇礼.左旋咪唑和双黄连治疗眼型Graves病[J].中国实用眼科杂志,1995,13(6):382.
[32]张太阳,张启发.黄芪对Graves病患者T淋巴细胞亚群的影响[J].江西中医学院学报,1995,(2):22.
[33]王晓敏,王晓玲.雷公藤多甙治疗甲亢突眼的临床研究[J].江苏中医药,1995,16(10):41.
[34]唐灵,梁志清.雷公藤多甙对Graves病甲状腺功能及自身抗体的影响[J].中国中西医结合杂志,2003,23(4):294-295.
[35]沐榕,陈美爱.针刺为主治疗甲状腺机能亢进稳定期浸润性突眼症的临床观察[J].中国中西医结合杂志,2000,20(3):226-227.
[36]王晓燕.针刺治疗突眼性甲状腺肿临床疗效观察[J].中国针灸,2002,22(1):13.
[37]陈修贵,孙克兴.针刺治疗Graves眼病患者突眼的免疫学机制探讨[J].中国中医药信息杂志,2004,11(5):381-382.
[38]李桂玲、刘原芳.挑治法治疗Graves眼病28例临床观察[J].中国中医急症,2006,15(7):728-729.
[39]黄立.中西药结合治疗眼型Graves病[J].中国中医眼科杂志,2000,10(4):223.
[40]唐爱华.中西医结合治疗甲亢突眼的临床观察[J].四川中医,2006,24(7):54-55.
[41]费大东.中西医结合治疗甲亢突眼35例[J].山东中医杂志,2004,23(8):485-486.
[42]李昌祁,阴慧清,张春凯,等.大庆地区十万人群Graves病流行病学凋查[J].中华医学杂志,2000,76(6):443.
[43]罗敏.Graves眼病的发病机制及其治疗策略[J].国外医学内分泌学分册,2003,23(6):372-373
[44]王爱萍.细胞因子在Graves眼病发病中的作用机理[J].国外医学内分泌学分册,2003,23(6):401-402.
[45]Noh JY,Hamada N,Inoue Y,etal.Thyroid-stimulating antibody is related to Graves'ophthalmopathy,but thyropin-binging inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves'disease [J].Thyroidism,2000,9:809-813.
[46]吴晓徽,陆汉魁,高云朝.甲状腺球蛋白的测量及临床应用价值[J].标记免疫分析与临床,2008,15(5):325-326.
[47]胡蜀红.Graves眼病的发病机理[J].国外医学内分泌学分册,2002,22(2):98-99.
[48]陈雷,李玉妹,滕卫平,等.Graves眼病IgG和细胞因子INF-Y对体外培养人眶后成纤维细胞的刺激作用[J].中国医科大学学报,2007,28(1):38-40.
[49]何为民.黏附分子在Graves眼病眼外肌原位表达的研究[J].中华眼科杂志,2001,37(4):267-268.
[50]何为民.Graves眼病的组织病理学研究[J].华西医学,2002,17(3):422-423.
[51]孙玲玲.Graves病候选基因多态性研究进展[J].国际遗传学杂志,2006,29(1):62-64.
[52]张胜兰,张秀英.Graves眼病的发病机理及治疗[J].山东医药,2001,4(6):57-58.
[53]孙华,焦秦.甲状腺相关眼病381例临床分析[J].中华内科杂志,2006,45(5):400-402.
[54]邹新农.Graves病眼眶的CT研究[J].中国CT和MRI杂志,2006,4(1):11-13.
[55]陈德才,朱泓,陈红艳,等.甲基强的松龙与地塞米松加氨甲蝶呤冲击治疗Graves眼病的近期临床 疗效观察[J].中华内分泌代谢杂志,2002,18(4):321-322.
[56]王坚.Groves眼病部分免疫抑制剂疗效探讨[J].中华内科杂志,2004,43(2):125-126.
[57]Heufelder AE.[J].Endocrinol Invest,1997,20(Suppl)7:50.
[58]Colao A etal.Eur[J].Endocrinol,2000,143(Suppl):S35.
[59]Krassas GE etal.Eur[J].Endocrinol,2001,144(4):311.
[60]BasehieriL,AntonelliA.Nardi5eral[J].ThyTOid,1998,7(4):579-585.
[61]Glinoerand Msehroogen:Aeta,Endoerinologiea(Copenh)1999,(2):149.
[62]曲宝林,王迎选,徐寿平.Graves眼病放射治疗121例临床观察[J].生物医学工程与临床,2007,11(3):210-211.
[63]Burch HB,Wartofsky L.Graves'ophthalmopathy:current concepts regarding pathogenesis and management[J].Eendocr REV,1993;14:747.
[64]郑筱萸主编.中药新药临床研究指导原则[M].中国科技出版社:2002.5.
[65]中国甲状腺疾病诊治指南.中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组,2007,4,15.
[66]陈灏珠.实用内科学(第12版)[M].北京:人民卫生出版社2005.
[67]国家技术监督局.中华人民共和国国家标准·中医临床诊疗术语·证候部分[S].北京:中国标准出版社,1997:4-8.
[68]岳式君,单忠艳,旷劲松,等.大剂量激素冲击疗法治疗浸润性突眼[J].中国医科大学学报,1996,25(3):316-317.
[69]薛明,冯怡.夏枯草化学成分及药理作用的研究概况[J].江苏中医药,2005,26(5):55-56.
[70]陈勤,曾炎贵,曹明成,等.夏枯草口服液抗炎镇痛作用研究[J].基层中医药杂志,2002,16(2):6.
[71]韩澎,崔亚君,郭洪祝,等.密蒙花化学成分及其活性研究[J].中草药,2004,35(10)1086-1090.
[72]宋毅,王玉娥,冯玲玲,等.枸杞多糖免疫调节作用的实验研究[J].湖北预防医学杂志,2000,11(3):161.
[73]施仁潮.枸杞子[M].杭州:浙江科学技术出版社,2002.12-22.
[74]邱静帆.车前子的药学研究及其应用[J].浙江中西医结合杂志,2002,12(1):55.
[75]张海燕.连翘化学成分及药理活性的研究进展[J].中药材,2000,23(10)657-660.
[76]舒华,向丽华.黄连药理作用及临床应用[J].甘肃中医,2004,17(12):5-6.
[77]许廷生,梁秀兰.黄连的临床应用[J].河南中医,2003,23(3)61.
[78]张秀明.茯苓药理作用研究概况[J].中药材,2001,24(6)446-449.
[79]冯宝民,余正江.炒白芥子中化学成分的研究[J].中草药,2008,39(3):331-334.
[80]李小莉,张迎庆.白芥子提取物的抗炎镇痛作用研究[J].现代中药研究与实践,2007,21(6):28-30.
[81]阮金兰,赵钟祥.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9):965-969.
[82]周强,栗占国.白芍总苷的药理作用及其在自身免疫性疾病中的应用[J].中国新药与临床杂志,2003,22(11):687-690.
[83]惠寿年.国内对甘草化学成分的研究进展[J].中草药,1999,30(4):313-3151.
[84]王惠敏.甘草药理作用及其临床应用[J].天津中医学院学报,2004,23(4):184-185.
[85]黄伟光,冯凭.Graves眼病治疗的现状与展望[J].国外医学·内分泌学分册,2001,21(6):317-318.
[86]杜建玲,李昌臣.甲基强的松龙冲击治疗54例Graves眼病的疗效观察[J].中国实用内科杂志2002,22(9):548.
[87]青华,张素华.大剂量甲基强的松龙静脉冲击治疗浸润性突眼的疗效观察[J].内分泌外科杂志,2008,2(2):109-111.